Context:

• In 2008, Harald zur Hausen was awarded the Nobel Prize for establishing that persistent infection with high-risk Human Papillomavirus causes cervical cancer—a major health burden, especially in low- and middle-income countries.
• His work enabled the development of preventive vaccines and diagnostic tests.
• Building on this, the World Health Organization launched a global initiative in 2018 to eliminate cervical cancer, followed by a formal strategy in 2020 endorsed by 194 countries, including India.
• This article highlights the global and Indian efforts to eliminate cervical cancer by tracing its link to Human Papillomavirus, examining the disease burden, challenges in screening, and the transformative role of vaccination and public health initiatives.

Cervical Cancer: Disease Burden and Prevention Challenges

• High Burden and Severe Impact
  • Cervical Cancer is the second most common cancer among women in India, with nearly one lakh new cases annually and about 50,000 deaths, accounting for roughly one-fourth of the global burden.
  • It disproportionately affects younger women, leading to significant loss of productive life years and causing immense physical, emotional, and financial distress.
  • Advanced-stage disease can result in severe complications such as urinary fistulas, chronic pain, bleeding, ureter obstruction, and renal failure.
• Treatment and Its Limitations
  • If detected early, cervical cancer is curable, but treatment often involves radical surgery, chemotherapy, or radiation, which carry substantial physical and financial costs.
  • Advanced or recurrent cases may require complex procedures like exenteration, along with long-term supportive care, making treatment burdensome.
• Prevention Through Screening
  • Cervical cancer is largely preventable due to its long precancerous phase of 10–15 years, known as Cervical Intraepithelial Neoplasia (CIN).
  • Since the 1940s, countries in the West have used Pap smear screening to detect both cancer and precancerous changes early, allowing treatment through simple, low-risk procedures without removing the uterus.
• Challenges in India and LMICs
  • In India and other low- and middle-income countries (LMICs), limited infrastructure and manpower have hindered large-scale screening.
  • Even screening all women above 30 once remains difficult, let alone regular three-year intervals.
  • Laboratory capacity constraints and reliance on outreach camps have restricted coverage.
  • Despite national screening programmes using visual inspection methods, coverage remains below 5%, and follow-up compliance is poor, with many women failing to return for confirmatory diagnosis and treatment.

HPV Vaccine: A Breakthrough in Cervical Cancer Prevention

• Introduction and Evolution of the Vaccine
  • The Human Papillomavirus vaccine, introduced in 2006, transformed the prevention of Cervical Cancer by offering primary protection against its main cause.
  • Initially administered in three doses, research has shown that two doses—and even a single dose—can provide 85–90% protection, making it more accessible and cost-effective.
• Safety and Global Adoption
  • With over 500 million doses administered worldwide (including nearly four million in India), extensive clinical trials and real-world data confirm that the vaccine is highly safe.
  • Reported side effects are limited to mild, temporary reactions, with no evidence of impact on fertility, reproductive health, or menstrual patterns.
• High Efficacy Against Cancer-Causing Strains
  • The vaccine provides near-complete protection against high-risk HPV strains, particularly HPV 16 and 18, which account for 70% of cervical cancers globally and about 85% in India.
• Global Success Stories
  • Countries such as Australia and United Kingdom, which adopted the vaccine early (2007–08), have already seen significant declines in precancerous lesions and cervical cancer cases.
  • Similar positive outcomes have been reported in Sweden, Denmark, Canada, and the United States.

Cervical Cancer Elimination: Expanding Access to Prevention

• WHO Targets and Global Vision
  • The World Health Organization aims to make Cervical Cancer a rare disease with incidence below 4 per 1,00,000.
  • To achieve this by 2030, countries must meet key targets:
    • 90% HPV vaccination for girls before age 15
    • 70% screening of women at ages 35 and 45
    • 90% treatment of detected cases
• India’s Progress and Gaps
• While India has made progress since adopting the global strategy, it is still far from meeting these targets, especially in vaccination coverage and screening.
• National HPV Vaccination Campaign
  • A major step forward is the launch of the National HPV Vaccination Campaign on February 28, 2026, reflecting strong political commitment to women’s health and reproductive rights.
  • The programme provides free vaccination for 14-year-old girls at government health facilities.
• Path Ahead: Awareness and Participation
  • Achieving elimination depends on public awareness and participation, particularly encouraging parents to vaccinate eligible girls.
  • Expanding access to vaccination and screening can significantly reduce disease burden.